ImCheck
AcquiredImchecktherapeutics.com
Marseille, France · Founded 2015 · $174.1M raised
- Headquarters
- Marseille
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- imchecktherapeutics.com
- Total Funding
- $174.1M
- Last Round
- $103.0M Series CJun 2022
- Rounds
- 4
About
ImCheck Therapeutics is a clinical-stage biotech pioneering immunomodulation through the butyrophilin (BTN) and BTN-like (BTNL) checkpoint molecule superfamily. The company designs next-generation immunotherapeutic antibodies targeting cancer, infectious disease, and autoimmune conditions. ImCheck was acquired by Ipsen in 2025 to expand its oncology pipeline.
Summary
ImCheck is a Biotech company based in Marseille, France, founded in 2015. It has raised $174.1M in total across 4 rounds, most recently a $103.0M Series C round in Jun 2022.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2022
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...